These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

218 related articles for article (PubMed ID: 4352743)

  • 1. Glucagon and prostaglandin E1 stimulation of cyclic adenosine 3', 5'-monophosphate levels and adenylate cyclase activity in benign hyperplastic nodules and malignant hepatomas of ethionine-treated rats.
    Chayoth R; Epstein SM; Field JB
    Cancer Res; 1973 Aug; 33(8):1970-4. PubMed ID: 4352743
    [No Abstract]   [Full Text] [Related]  

  • 2. Comparison of cyclic adenosine 3':5'-monophosphate and cyclic guanosine 3':5'-monophosphate levels, cyclases, and phosphodiesterases in Morris hepatomas and liver.
    Hickie RA; Thompson WJ; Strada SJ; Couture-Murillo B; Morris HP; Robison GA
    Cancer Res; 1977 Oct; 37(10):3599-606. PubMed ID: 20224
    [No Abstract]   [Full Text] [Related]  

  • 3. Increased guanylate cyclase activity and guanosine 3',5'-monophosphate content in ethionine-induced hepatomas.
    DeRubertis FR; Craven P
    Cancer Res; 1977 Jan; 37(1):15-21. PubMed ID: 11887
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparative adenylate cyclase activities in homogenate and plasma membrane fractions of Morris hepatoma 5123tc (h).
    Hickie RA; Jan SH; Datta A
    Cancer Res; 1975 Mar; 35(3):596-600. PubMed ID: 163685
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Regulation of the adenylate cyclase system in transplantable hepatomas.
    Criss WE; Morris HP
    Cancer Res; 1976 May; 36(5):1740-3. PubMed ID: 178431
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inhibition of glucagon-mediated increases in hepatic cyclic adenosine 3', 5'-monophosphate by prostaglandin E1 and E2.
    DeRubertis FR; Zenser TV; Curnow RT
    Endocrinology; 1974 Jul; 95(1):93-101. PubMed ID: 4365622
    [No Abstract]   [Full Text] [Related]  

  • 7. Effects of prostaglandins on hepatic adenylate cyclase activity and cyclic adenosine 3',5',-monophosphate content.
    Zenser TV; DeRubertis FR; Curnow RT
    Endocrinology; 1974 May; 94(5):1404-10. PubMed ID: 4362972
    [No Abstract]   [Full Text] [Related]  

  • 8. Endocrine control of cyclic adenosine 3',5'-monophosphate levels in several Morris hepatomas.
    Butcher FR; Scott DF; Potter VR; Morris HP
    Cancer Res; 1972 Oct; 32(10):2135-40. PubMed ID: 4343008
    [No Abstract]   [Full Text] [Related]  

  • 9. Sequential alterations in the hepatic content and metabolism of cyclic AMP and cyclic GMP induced by DL-ethionine: evidence for malignant transformation of liver with a sustained increase in cyclic AMP.
    DeRubertis FR; Craven PA
    Metabolism; 1976 Dec; 25(12):1611-25. PubMed ID: 186692
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of prostaglandins on adenylate cyclase activities in membranes from liver and transplantable hepatomas.
    Pradhan TK; Criss WE
    Cancer Biochem Biophys; 1976 Aug; 1(5):239-43. PubMed ID: 184916
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hyperglucagonemia and altered responsiveness of hepatic adenylate cyclase-adenosine 3',5'-monophosphate system to hormonal stimulation during chronic ingestion of DL-ethionine.
    Craven PA; Derubertis FR
    Biochim Biophys Acta; 1977 Apr; 497(2):415-27. PubMed ID: 192313
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Regulation of adenyl cyclase in hepatomas of different growth rates.
    Allen DO; Munshower J; Morris HP; Weber G
    Cancer Res; 1971 May; 31(5):557-60. PubMed ID: 4325838
    [No Abstract]   [Full Text] [Related]  

  • 13. Induction of enzymes by glucagon, glucose repression, adenosine 3',5'-monophosphate concentration during carcinogenesis and in Morris 6918A hepatoma.
    Sudilovsky O; Gunter R
    Cancer Res; 1975 Apr; 35(4):1069-74. PubMed ID: 234792
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Independence of pituitary tumor-mediated suppression of growth hormone secretion and cyclic 3',5'-adenosine monophosphate production.
    MacLeod RM; Lehmeyer JE
    Cancer Res; 1973 Apr; 33(4):843-8. PubMed ID: 4348775
    [No Abstract]   [Full Text] [Related]  

  • 15. Cyclic 3',5'-nucleotide monophosphate phosphodiesterase activity in hepatomas of different growth rates.
    Rhoads AR; Morris HP; West WL
    Cancer Res; 1972 Dec; 32(12):2651-5. PubMed ID: 4345399
    [No Abstract]   [Full Text] [Related]  

  • 16. Activity and hormone responsiveness of adenyl cyclase during induction of tumors in rat liver with 3'-methyl-4-dimethylaminoazobenzene.
    Boyd H; Louis CJ; Martin TJ
    Cancer Res; 1974 Jul; 34(7):1720-5. PubMed ID: 4365235
    [No Abstract]   [Full Text] [Related]  

  • 17. Effects of adrenergic agonists and antagonists on adenylate cyclase activity of dog heart and liver.
    Mayer SE
    J Pharmacol Exp Ther; 1972 Apr; 181(1):116-25. PubMed ID: 4335168
    [No Abstract]   [Full Text] [Related]  

  • 18. [Cyclic AMP - its importance for clinical medicine].
    Schwarzmeier JD
    Subsid Med; 1975; 1-2():21-7. PubMed ID: 163557
    [No Abstract]   [Full Text] [Related]  

  • 19. Anomalous adenosine cyclic 3':5'-monophosphate responses to glucagon in patients with hepatocellular carcinoma.
    Pun KK; Ho PW; Yeung RT
    Cancer Res; 1986 Apr; 46(4 Pt 2):2152-4. PubMed ID: 3004721
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Functional and structural alterations of liver ergastoplasmic membranes during DL-ethionine hepatocarcinogenesis.
    Gravela E; Feo F; Canuto RA; Garcea R; Gabriel L
    Cancer Res; 1975 Nov; 35(11 Pt 1):3041-7. PubMed ID: 241483
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.